Hypera S.A. (OTCMKTS:HYPMY) Sees Significant Increase in Short Interest

Hypera S.A. (OTCMKTS:HYPMY) saw a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 11,100 shares, a growth of 270.0% from the May 31st total of 3,000 shares. Based on an average daily volume of 13,400 shares, the short-interest ratio is presently 0.8 days.

Hypera Price Performance

OTCMKTS HYPMY remained flat at $5.39 during trading hours on Thursday. The company’s stock had a trading volume of 6,138 shares, compared to its average volume of 26,169. The company’s 50-day simple moving average is $5.58 and its 200 day simple moving average is $6.37. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.89 and a quick ratio of 1.38. Hypera has a 12 month low of $5.08 and a 12 month high of $10.08.

Hypera (OTCMKTS:HYPMY) last posted its quarterly earnings results on Friday, April 26th. The company reported $0.12 earnings per share for the quarter. The company had revenue of $368.97 million for the quarter. Hypera had a return on equity of 16.14% and a net margin of 21.68%.

About Hypera

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.